| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Fumagillol targets methionyl aminopeptidase 2 (METAP2), a key enzyme involved in protein processing. METAP2 removes the N-terminal methionine from newly synthesized proteins, a critical step in protein maturation. By inhibiting METAP2 with an IC50 of 230 nM, fumagillol disrupts this process, leading to its anti-angiogenic and anti-tumor effects. The compound's activity against METAP2 is central to its diverse biological activities.
|
|---|---|
| ln Vitro |
On CHO cells, fumagillol derivatives do not appear to have any cytotoxic effects [1].
In vitro, fumagillol inhibits methionyl aminopeptidase 2 (METAP2) with an IC50 of 230 nM for the human enzyme. Fumagillol derivatives have no significant cytotoxic effect on CHO cells. The compound's anti-angiogenic activity is mediated through its inhibition of METAP2, which affects endothelial cell proliferation and migration. Its anti-inflammatory and antibacterial activities have also been demonstrated in various in vitro systems. |
| ln Vivo |
In vivo, fumagillol exhibits anti-angiogenic, anti-tumor, and anti-inflammatory properties. As a precursor to fumagillin and TNP-470, its in vivo effects are related to its conversion to these active compounds. Fumagillin is a potent and selective inhibitor of angiogenesis. The compound's activity against parasites has also been observed. Its in vivo efficacy has been demonstrated in various preclinical models.
|
| Enzyme Assay |
In vitro enzyme assays for fumagillol involve measuring the inhibition of methionyl aminopeptidase 2 (METAP2) activity using purified enzyme preparations. The compound is incubated with METAP2 and a peptide substrate, and the removal of the N-terminal methionine is measured using HPLC or mass spectrometry. The IC50 value of 230 nM is determined from dose-response curves. Selectivity against other aminopeptidases can be assessed using similar assays.
|
| Cell Assay |
In vitro cell-based assays for fumagillol involve treating endothelial cells or cancer cells with the compound to assess its anti-angiogenic and anti-tumor effects. Cell proliferation is measured using MTT or similar assays. Endothelial tube formation assays assess the compound's ability to inhibit angiogenesis. The compound's effects on cell viability and signaling pathways are studied in various cell lines. Fumagillol derivatives show no significant cytotoxic effect on CHO cells.
|
| Animal Protocol |
In vivo animal experiments for fumagillol are typically conducted using its active derivatives, fumagillin or TNP-470. These compounds have been studied in various tumor xenograft models to assess their anti-angiogenic and anti-tumor efficacy. The compounds are administered via injection, and tumor growth inhibition is monitored. Efficacy endpoints include tumor volume reduction and assessment of angiogenesis markers.
|
| ADME/Pharmacokinetics |
Fumagillol has a molecular weight of 282.38 and a molecular formula of C16H26O4. It is a sesquiterpenoid with a spirocyclic epoxide structure. The compound is soluble in chloroform, ethanol, and methanol. It is a solid with a purity of ≥95%. It is typically stored at -20°C and shipped at room temperature. Its formal name is (3R,4S,5S,6R)-.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for fumagillol is not extensively reported. As a precursor to potent angiogenesis inhibitors, its safety profile is related to its effects on endothelial cell function. The compound is generally well-tolerated in preclinical studies at therapeutic doses. Comprehensive toxicological studies would be required for therapeutic development. Standard safety precautions should be taken when handling the compound.
|
| References | |
| Additional Infomation |
Fumagillol is a sesquiterpene compound with antibacterial activity and can be used as an antibacterial agent. It is a spirocyclic epoxide, secondary alcohol, and sesquiterpene compound. Fumagillol has been reported to have been detected in both Penicillium japonicum and Aspergillus fumigatus, and relevant data are available for reference.
Fumagillol is a sesquiterpenoid natural product and a direct precursor of the potent angiogenesis inhibitors TNP-470 and fumagillin. It inhibits methionyl aminopeptidase 2 (METAP2) with an IC50 of 230 nM. The compound exhibits anti-angiogenic, anti-tumor, anti-inflammatory, and antibacterial activities. Fumagillol is derived from Aspergillus fumigatus. It is a research compound with applications in angiogenesis and cancer research. |
| Molecular Formula |
C16H26O4
|
|---|---|
| Molecular Weight |
282.37524
|
| Exact Mass |
282.183
|
| CAS # |
108102-51-8
|
| PubChem CID |
222778
|
| Appearance |
White to off-white solid powder
|
| Vapour Pressure |
1.08E-07mmHg at 25°C
|
| LogP |
2.055
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
417
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CC(=CC[C@@H]1[C@@](O1)(C)[C@H]2[C@@H]([C@@H](CC[C@]23CO3)O)OC)C
|
| InChi Key |
CEVCTNCUIVEQOY-JQOWZUPLSA-N
|
| InChi Code |
InChI=1S/C16H26O4/c1-10(2)5-6-12-15(3,20-12)14-13(18-4)11(17)7-8-16(14)9-19-16/h5,11-14,17H,6-9H2,1-4H3/t11-,12-,13-,14-,15+,16+/m1/s1
|
| Chemical Name |
(3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-ol
|
| Synonyms |
Gelcohol NSC-9665 NSC 9665 NSC9665
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~354.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5413 mL | 17.7066 mL | 35.4133 mL | |
| 5 mM | 0.7083 mL | 3.5413 mL | 7.0827 mL | |
| 10 mM | 0.3541 mL | 1.7707 mL | 3.5413 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA